We continue to see patients and ensure they receive high-quality cancer care in a safe environment.
Review our enhanced safety measures. Learn about our appointment types or call 913-588-1227 to schedule.
The meeting featured a variety of sessions including a Clinical Plenary session, led by Weijing Sun, MD, director of Medical Oncology.
Task force is guided by strategic priorities, include addressing areas of unmet clinical need, unanswered clinical questions and potential new approaches to disease treatment.
More than 42,750 people from 138 countries attended this year’s American Society of Clinical Oncology (ASCO) annual meeting. Held virtually for the first time ever, the meeting featured 2,600 faculty and speakers and 5,300 abstracts delivering the latest news in cancer research. Members of The University of Kansas Cancer Center discussed their key findings and presented dozens of abstracts.
A tiny tool developed by researchers could help detect and track the spread of tumors in breast cancer patients.
Incysus Therapeutics, Inc., a biopharmaceutical company focused on delivering an gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced that the first patient in a phase I clinical study, Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide, has been treated at The University of Kansas Cancer Center.
Research arm provides COVID-19 testing for more than 500 cancer patients
Dr. Conaway has been elected for her distinguished and continuing achievements in original scientific research. Membership in the NAS is considered one of the highest honors given to a scientist in the United States.
Ronald Chen, MD, MPH, Brandmeyer Chair and Professor of Radiation Oncology, has been named the new principal investigator for NRG Oncology clinical trials efforts at The University of Kansas Cancer Center. He takes the place of Joshua Mammen, MD, PhD, FACS, division chief of Surgical Oncology, who served in the position for several years.
The distinction is given to those who have carried out efforts that benefit ASCO, the specialty of oncology and the patients they serve.
KU Cancer Center researcher participates in virtual peer-to-peer panel on expanding treatment opportunities
Researchers have identified a novel approach to overcome drug resistance in leukemia
Funds will be crucial to the KU Cancer Center’s competitive application for National Cancer Institute (NCI) comprehensive cancer center designation.
Social media program 'Bench to Bedside' features cancer research and treatment thought leaders.
The University of Kansas Cancer Center has once again distinguished itself as one of the nation’s best by earning the 2019 Outstanding Achievement Award from the American College of Surgeons’ Commission on Cancer. The cancer center was one of 48 select cancer programs across the country to achieve the distinction.
A historical review authored by members of KU Cancer Center chronicles decades of immune-based research leading to a new frontier in cancer treatment, CAR T-cell therapy.